title: Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma.
abstract: Thirty-five dogs with appendicular osteosarcoma underwent amputation and chemotherapy with cisplatin and doxorubicin every 21 days for up to four cycles. Sixteen dogs completed all four cycles. Two dogs had therapy discontinued because of metastases. The remaining 17 dogs experienced toxicities necessitating protocol alteration or discontinuation. The median survival time of 300 days was not improved over previously reported single-agent protocols, but the 10 dogs that survived to a year lived a median of 510 days.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506, USA.
authors.forename: Ruthanne
authors.initials: R
authors.lastname: Chun
authors.forename: Laura D
authors.initials: LD
authors.lastname: Garrett
authors.forename: Carolyn
authors.initials: C
authors.lastname: Henry
authors.forename: Michelle
authors.initials: M
authors.lastname: Wall
authors.forename: Annette
authors.initials: A
authors.lastname: Smith
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Azene
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin